A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma.

Trial Profile

A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Urelumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 18 Oct 2016 Results of integrated safety and preliminary pharmacodynamic data analysis from this and other two studies (n=346) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 15 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Planned end date changed from 1 Dec 2009 to 1 Aug 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top